Re-optimization Based Online Adaptive Radiotherapy of Anal Cancer

ROAR-A: Re-optimization Based Online Adaptive Radiotherapy of Anal Cancer

Sponsors

Lead Sponsor: Herlev Hospital

Source Herlev Hospital
Brief Summary

A single-arm, prospective, Phase II, single-center clinical trial that will investigate if daily online adaptive radiotherapy for anal cancer will significantly reduce early treatment-related GI toxicity compared with the historically reported rate for non-adaptive intensity modulated radiation therapy (IMRT).
Overall Status Recruiting
Start Date 2022-01-01
Completion Date 2031-01-01
Primary Completion Date 2026-01-01
Phase Phase 2
Study Type Interventional
Primary Outcome
Measure Time Frame
Early Rate of Common Terminology Criteria for Adverse Events (CTCAE) Gastrointestinal Toxicity grade 2 or more (scale from 0-5, 5 being the highest) from mid-treatment to 3 months after end of treatment
Secondary Outcome
Measure Time Frame
All Early Common Terminology Criteria for Adverse Events (CTCAE) Treatment Related Toxicities. Grade 1-5 (5 being the highest) from mid-treatment to 3 months after end of treatment
All Late Common Terminology Criteria for Adverse Events (CTCAE) Treatment Related Toxicities From 3 months after end of treatment to 5 years follow-up
Patient Reported Outcomes (PRO) from baseline to 5 years follow-up
European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Assessment from baseline to 5 years follow-up
Progression Free Survival From time of inclusion to disease progression, assessed up to 5 years follow-up
Overall Survival From time of inclusion to death from any cause, assessed up to 5 years follow-up
Disease Free Survival From time of inclusion to death from bladder cancer, assessed up to 5 years follow-up
Treatment Related Hospitalization From of start of radiation therapy through 5 year follow-up
Enrollment 205
Condition
Intervention

Intervention Type: Radiation

Intervention Name: online adaptive radiotherapy

Description: Online adaptive radiotherapy compared to standard non-adaptive Image-Guided Radiotherapy

Arm Group Label: Online adaptive radiotherapy

Other Name: Varian Ethos Adaptive Radiation Therapy

Eligibility

Criteria:

Inclusion Criteria: - Biopsy-verified anal cancer - Eligible for curative intended radiotherapy - Written and oral consent Exclusion Criteria: - Other malignant disease within the past 5 years (excluding basal cell carcinoma)

Gender:

All

Minimum Age:

18 Years

Maximum Age:

N/A

Healthy Volunteers:

No
Overall Official
Last Name Role Affiliation
Eva S Serup-Hansen, MD, PhD Principal Investigator Herlev og Gentofte Hospital
Overall Contact

Last Name: Eva Serup-Hansen, MD, PhD

Phone: +4538689084

Email: [email protected]

Location
Facility: Status: Contact: Contact Backup: Investigator: Oncology dept, Herlev and Gentofte Hospital Eva S Serup-Hansen, MD, PhD +4538689084 [email protected] Eva Serup-Hansen, MD, PhD Principal Investigator katrine S Storm, MD Sub-Investigator Anna-Lene Fromm, MD Sub-Investigator Laura V Diness, MD Sub-Investigator
Location Countries

Denmark
Verification Date

2022-08-01
Responsible Party

Type: Principal Investigator

Investigator Affiliation: Herlev Hospital

Investigator Full Name: Eva Serup-Hansen

Investigator Title: Clinical oncologist, MD, PhD

Keywords
Has Expanded Access No
Condition Browse
Number Of Arms 1
Arm Group

Label: Online adaptive radiotherapy

Type: Experimental

Description: Daily online adaptive radiotherapy

Acronym ROAR-A
Patient Data Undecided
Study Design Info

Allocation: N/A

Intervention Model: Single Group Assignment

Primary Purpose: Treatment

Masking: None (Open Label)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact [email protected]. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Anal Cancer

Clinical Trials on online adaptive radiotherapy

Medical Conditions

Sponsors and Collaborators

Drug Interventions

CROs by country

CROs in Trinidad & Tobago

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations